Live Breaking News & Updates on Announces Preliminary Efficacy Achievement

Stay updated with breaking news from Announces preliminary efficacy achievement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |NetScientific PLC Announcements | NetScientific PLC: PDS Phase 2 Trial Update

Investegate announcements from NetScientific PLC, PDS Phase 2 Trial Update ....

United States , United Kingdom , City Of , Jared Weiss , Nicholas Johnson Paul Mcmanus , Darshan Patel , Laurenv Wood , Ilian Iliev , Lineberger Comprehensive Cancer Centre , London Stock Exchange , Drug Administration , Biotechnology Corporation The Company , Lineberger Comprehensive Cancer Center , United States Securities Exchange , Biotechnology Corporation Nasdaq , Announces Preliminary Efficacy Achievement , Combination With , Advanced Head , Section Chief , Neck Oncology , Chapel Hill School , Lead Principal Investigator , Chief Medical Officer , United States Securities Exchange Act , United States Securities Act , Financial Adviser ,

Investegate |NetScientific PLC Announcements | NetScientific PLC: PDS Phase II Trial Update & Restoration of Trading

PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute

·
The National Cancer Institute s (NCI) Phase II clinical study of PDS Biotech s PDS0101 for HPV-associated cancers has achieved its preliminary objective response.
·
Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients
·
Milestone for
treatment of
HPV-associated cancers

NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces

that its portfolio company PDS Biotechnology Corporation ( PDS ) (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute s (NCI) Phase II clinical study of PD ....

United States , James Gulley , Anna Dunphy Nick , Darshan Patel , Frank Bedu , Julius Strauss , Jeffrey Schlom , Nicholas Johnson , Stephen Smith , Lauren Wood , Ilian Iliev , Development Agreement , National Cancer Institute , University Of Texas Md Anderson Cancer Center , Cancer Research Laboratory Of Tumor Immunology , Biotechnology Corporation , Biotechnology Corporation Nasdaq , Genitourinary Malignancies Branch , Announces Preliminary Efficacy Achievement , National Cancer , Non Executive Director , Cancer Research , Tumor Immunology , Chief Medical Officer , Cooperative Research , Frank Bedu Addo ,